Prostate Cancer Diagnosis and Management

Pre-Test Conditions and PSA Measurement

Patients should abstain from ejaculation for 48 hours before testing, avoid infection or inflammation, and refrain from recent instrumentation to ensure accurate PSA test results, as recommended by the National Comprehensive Cancer Network and the American Urological Association 1, 2, 3
5α-reductase inhibitors (such as finasteride and dutasteride) typically cause a ~50% decrease in PSA within 6-12 months of starting therapy, and must be considered when interpreting results, as noted by the National Comprehensive Cancer Network 2
Age-specific PSA reference ranges should be considered when interpreting PSA values, as emphasized by the American College of Physicians and The Journal of Urology guidelines 4, 2

The American College of Radiology recommends using the most accurate imaging method for detecting local recurrence, which helps identify lesions that require targeted biopsy, and considering imaging when PSA ≥10 ng/mL with Gleason score 4-5, PSA >15 ng/mL with Gleason score ≥7, presence of bone pain, or locally advanced tumor 5
The following table outlines indications for imaging based on PSA level and Gleason score:

Transrectal ultrasound-guided biopsy should be performed under antibiotic coverage and local anesthesia, with a minimum of 10-12 cores required for adequate sampling, as recommended by the European Society for Medical Oncology 8
Consideration of multiparametric MRI before biopsy may improve targeting of suspicious areas, as recommended by the NCCN guidelines 2
A combined approach of MRI-targeted biopsy plus systematic sampling is optimal, as recommended by the NCCN 9, 10, 11, 4, 2

Patients should undergo initial PSA monitoring every 6-12 months, though high-risk patients may require testing as frequently as every 3 months, as recommended by the National Comprehensive Cancer Network 1
Consideration of additional factors such as family history of prostate cancer, ethnicity, and free/total PSA ratio is recommended for risk assessment by the National Comprehensive Cancer Network 12
Risk calculators and nomograms can improve efficiency in selecting men for biopsy, as noted by 13
The rate of PSA rise is often more important than the absolute value in predicting aggressive disease, as noted by the NCCN 14, 11
PSA levels between 4.0-10.0 ng/mL have a positive predictive value of 25-35% for prostate cancer, while PSA >10 ng/mL has a positive predictive value of 43-65% for prostate cancer 4

Treatment options depend on cancer stage, grade, and patient factors, and may include active surveillance, surgery, radiation therapy, or androgen deprivation therapy, as recommended by the NCCN 2
For localized disease with higher grade, radiation therapy with or without androgen deprivation therapy (ADT) may be considered, as recommended by the NCCN 14
Androgen deprivation therapy (ADT) is the standard initial treatment for symptomatic metastatic disease, according to the NCCN 15
For castration-resistant prostate cancer (CRPC) with symptoms, radium-223, docetaxel, abiraterone, or enzalutamide should be considered based on patient characteristics, as suggested by the European Association of Urology and the American Society of Clinical Oncology 16, 17
After radical prostatectomy, PSA should be undetectable (<0.4 ng/mL), and after radiation therapy, three consecutive PSA rises with at least 2 years of follow-up indicates biochemical recurrence, as recommended by the American College of Surgeons and the American Society for Radiation Oncology 6
Routine PSA monitoring should be resumed every 6-12 months, and if biopsy is negative, PSA monitoring should continue every 6 months for the first year, then annually if stable 1
Calcium and vitamin D supplementation, denosumab or zoledronic acid, and dental evaluation before starting bone-targeted therapy may be recommended for patients with bone metastases, as suggested by the European Society for Medical Oncology 18